Kramm, Christof M.

[["dc.bibliographiccitation.journal","Brain Pathology"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","zur Muehlen, Anja"],["dc.contributor.author","Wolff, J."],["dc.contributor.author","Kwiecien, Robert"],["dc.contributor.author","Kramm, C."],["dc.date.accessioned","2018-11-07T09:35:54Z"],["dc.date.available","2018-11-07T09:35:54Z"],["dc.date.issued","2014"],["dc.format.extent","74"],["dc.identifier.isi","000342165800267"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32494"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","18th International Congress of Neuropathology"],["dc.relation.eventlocation","Rio de Janeiro, BRAZIL"],["dc.relation.issn","1750-3639"],["dc.relation.issn","1015-6305"],["dc.title","Histopathological grading according to the WHO classification of CNS tumors and H3.3K27 mutational status represent independent prognostic markers in pediatric high grade gliomas"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","27"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","35"],["dc.bibliographiccitation.volume","114"],["dc.contributor.author","Pfaff, Elke"],["dc.contributor.author","El Damaty, Ahmed"],["dc.contributor.author","Balasubramanian, Gnana Prakash"],["dc.contributor.author","Blattner-Johnson, Mirjam"],["dc.contributor.author","Worst, Barbara C."],["dc.contributor.author","Stark, Sebastian"],["dc.contributor.author","Witt, Hendrik"],["dc.contributor.author","Pajtler, Kristian W."],["dc.contributor.author","van Tilburg, Cornelis M."],["dc.contributor.author","Witt, Ruth"],["dc.contributor.author","Milde, Till"],["dc.contributor.author","Jakobs, Martin"],["dc.contributor.author","Fiesel, Petra"],["dc.contributor.author","Frühwald, Michael C."],["dc.contributor.author","Hernáiz Driever, Pablo"],["dc.contributor.author","Thomale, Ulrich W."],["dc.contributor.author","Schuhmann, Martin U."],["dc.contributor.author","Metzler, Markus"],["dc.contributor.author","Bochennek, Konrad"],["dc.contributor.author","Simon, Thorsten"],["dc.contributor.author","Dürken, Matthias"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Knirsch, Stephanie"],["dc.contributor.author","Ebinger, Martin"],["dc.contributor.author","von Bueren, André O."],["dc.contributor.author","Pietsch, Torsten"],["dc.contributor.author","Herold-Mende, Christel"],["dc.contributor.author","Reuss, David E."],["dc.contributor.author","Kiening, Karl"],["dc.contributor.author","Lichter, Peter"],["dc.contributor.author","Eggert, Angelika"],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Pfister, Stefan M."],["dc.contributor.author","Jones, David T.W."],["dc.contributor.author","Bächli, Heidi"],["dc.contributor.author","Witt, Olaf"],["dc.date.accessioned","2020-12-10T14:23:39Z"],["dc.date.available","2020-12-10T14:23:39Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.ejca.2019.03.019"],["dc.identifier.issn","0959-8049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72003"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","611"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Pediatric Blood & Cancer"],["dc.bibliographiccitation.lastpage","617"],["dc.bibliographiccitation.volume","63"],["dc.contributor.author","Weber, Marie L."],["dc.contributor.author","Schneider, Dominik T."],["dc.contributor.author","Offenmüller, Sonja"],["dc.contributor.author","Kaatsch, Peter"],["dc.contributor.author","Einsiedel, Hagen Graf"],["dc.contributor.author","Benesch, Martin"],["dc.contributor.author","Claviez, Alexander"],["dc.contributor.author","Ebinger, Martin"],["dc.contributor.author","Kramm, Christof"],["dc.contributor.author","Brecht, Ines B."],["dc.date.accessioned","2021-06-01T10:47:12Z"],["dc.date.available","2021-06-01T10:47:12Z"],["dc.date.issued","2015"],["dc.identifier.doi","10.1002/pbc.25839"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85519"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","1545-5009"],["dc.title","Pediatric Colorectal Carcinoma is Associated With Excellent Outcome in the Context of Cancer Predisposition Syndromes"],["dc.title.alternative","Pediatric Colorectal Carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","8"],["dc.bibliographiccitation.volume","81"],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Krämer, Nadja"],["dc.contributor.author","Hoffmann, Marion"],["dc.contributor.author","Wiese, Maria"],["dc.contributor.author","Beilken, Andreas"],["dc.contributor.author","Corbacioglu, Selim"],["dc.contributor.author","Dilloo, Dagmar"],["dc.contributor.author","Hernaiz Driever, Pablo"],["dc.contributor.author","Scheurlen, Wolfram"],["dc.contributor.author","Kulozik, Andreas"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","von Bueren, André"],["dc.contributor.author","Dürken, Matthias"],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2018-10-10T07:47:12Z"],["dc.date.available","2018-10-10T07:47:12Z"],["dc.date.issued","2017"],["dc.description.abstract","Temozolomide (TMZ) is widely used in high-grade glioma (HGG). There is a major concern of treatment-induced secondary haematological malignancies (SHMs). Due to the poor overall survival of HGG patients, the true incidence is yet elusive. Thus, the aim of this study was to determine the risk of SHMs following TMZ in paediatric HGG. We analysed 487 patients from the HIT-HGG database of the German-speaking Society of Pediatric Oncology and Hematology with follow up beyond 1 year. The incidence of SHM was 7.7 ± 3.2% at 10 years. No SHM occurred in 194 patients after first-line TMZ therapy, but four out of 131 patients treated with TMZ for relapse following first-line multiagent chemotherapy experienced SHM (20% at 10 years; p = 0.041). SHMs occurred in two out of 162 patients who underwent multiagent chemotherapy without TMZ (4.1% at 10 years). Gender, patient age and acute haematological toxicity during treatment did not affect the incidence of SHMs. Data of our cohort do not indicate an increased risk of SHM following TMZ treatment when compared to previous chemotherapy regimen. However, if TMZ is administered as a second-line treatment following conventional chemotherapy regimen, the risk might be disproportionately increasing."],["dc.fs.pkfprnr","58469"],["dc.identifier.doi","10.1016/j.ejca.2017.04.023"],["dc.identifier.fs","633320"],["dc.identifier.pmid","28586748"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15921"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1879-0852"],["dc.title","Haematological malignancies following temozolomide treatment for paediatric high-grade glioma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1468"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Anti-Cancer Agents in Medicinal Chemistry"],["dc.bibliographiccitation.lastpage","1473"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Kuehnoel, Caspar D."],["dc.contributor.author","Staege, Martin S."],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2018-11-07T10:19:46Z"],["dc.date.available","2018-11-07T10:19:46Z"],["dc.date.issued","2016"],["dc.description.abstract","Malignant gliomas are tumors with a very unfavorable prognosis. They are characterized by rapid proliferation and invasion in the surrounding healthy tissue. Complete resection of the tumor is still the most important therapeutic option. Despite a variety of therapy modifications in the last years, long term survivors are still rare. Dendritic cell vaccination (DCV) might offer a new therapy option for the treatment of malignant gliomas. Hereby, tumorlysate pulsed dendritic cells (TPDC) can prime T cells to generate anti-tumor immune responses. Lenalidomide is an immune-modulatory piperidine-dione that has demonstrated activity especially in the treatment of hematopoietic malignancies. Here, we tested the combination of DCV and lenalidomide in an in vitro model for immunotherapy of malignant gliomas. No changes of T or NK cell subsets were observed when lenalidomide was used. In addition, interferon gamma enzyme linked immunospot (ELISPOT) showed no effects after priming of autologous peripheral blood mononuclear cells (PBMC) with TPDC and challenge with tumor cells. Although analyses of supernatants did not show higher amounts of interferon gamma and tumor necrosis factor alpha in the presence of lenalidomide, enhanced immune reaction by lenalidomide was detectable by granzyme B ELISPOT. Significantly higher numbers of spots were detected after challenge of TPDC-primed PBMC with tumor cells in the case that lenalidomide was present in the culture medium during priming. Our data suggest that the combination of DCV with lenalidomide might improve immunotherapy for malignant gliomas."],["dc.description.sponsorship","Celgene"],["dc.identifier.doi","10.2174/1871520616666160219131657"],["dc.identifier.isi","000390325500010"],["dc.identifier.pmid","26891975"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41731"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bentham Science Publ Ltd"],["dc.relation.issn","1875-5992"],["dc.relation.issn","1871-5206"],["dc.title","Lenalidomide in an in vitro Dendritic Cell Model for Malignant Gliomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","138"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","143"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Kewitz, Stefanie"],["dc.contributor.author","Stiefel, Martina"],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Staege, Martin S."],["dc.date.accessioned","2018-11-07T09:47:07Z"],["dc.date.available","2018-11-07T09:47:07Z"],["dc.date.issued","2014"],["dc.description.abstract","We analyzed the methylation status of the 06-methylguanine-DNAmethyltransferase (MGMT) promoter and mRNA expression in HL cells and assessed the response of these cells to dacarbazine. Expression of MGMT correlated with the presence of non-methylated promoters and cell lines with non-methylated promoters showed increased resistance against dacarbazine. KM-H2 cells expressed fusion transcripts between MGMT and proline-rich coiled-coil 2B (PRRC2B) but no wild type MGMT transcripts. Dacarbazine sensitivity suggested that fusion transcripts are translated into a protein with reduced functionality. MGMT promoter methylation predicts dacarbazine sensitivity of HL cells and it might be interesting to analyze this factor in HL patients. (C) 2013 Elsevier Ltd. All rights reserved."],["dc.identifier.doi","10.1016/j.leukres.2013.11.001"],["dc.identifier.isi","000329058900021"],["dc.identifier.pmid","24284332"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35037"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0145-2126"],["dc.title","Impact of 06-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine resistance of Hodgkin's lymphoma cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1182"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Molecular Imaging & Biology"],["dc.bibliographiccitation.lastpage","1191"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Kewitz-Hempel, Stefanie"],["dc.contributor.author","Kurch, Lars"],["dc.contributor.author","Cepelova, Michaela"],["dc.contributor.author","Volkmer, Ines"],["dc.contributor.author","Sauerbrey, Axel"],["dc.contributor.author","Conrad, Elke"],["dc.contributor.author","Knirsch, Stephanie"],["dc.contributor.author","Pöpperl, Gabriele"],["dc.contributor.author","Steinbach, Daniel"],["dc.contributor.author","Beer, Ambros J."],["dc.contributor.author","Kramm, Christof M."],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Erdlenbruch, Bernhard"],["dc.contributor.author","Reinbold, Wolf-Dieter"],["dc.contributor.author","Odparlik, Andreas"],["dc.contributor.author","Sabri, Osama"],["dc.contributor.author","Kluge, Regine"],["dc.contributor.author","Staege, Martin S."],["dc.date.accessioned","2020-12-10T14:11:58Z"],["dc.date.available","2020-12-10T14:11:58Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1007/s11307-019-01350-5"],["dc.identifier.eissn","1860-2002"],["dc.identifier.issn","1536-1632"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71264"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Impact of rs12917 MGMT Polymorphism on [18F]FDG-PET Response in Pediatric Hodgkin Lymphoma (PHL)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S234"],["dc.bibliographiccitation.journal","European Journal of Neurology"],["dc.bibliographiccitation.lastpage","S235"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Oenuegoeren, M. Dogan"],["dc.contributor.author","Halve, S."],["dc.contributor.author","Haensch, C. A."],["dc.contributor.author","Isenmann, S."],["dc.contributor.author","Katzenschlager, Regina"],["dc.contributor.author","Kramme, C."],["dc.contributor.author","Lohner, H."],["dc.contributor.author","Monotti, R."],["dc.contributor.author","Schaebitz, W.-R."],["dc.contributor.author","Stoeck, Katharina"],["dc.contributor.author","Strittmatter, Malte"],["dc.contributor.author","Stoegbauer, F."],["dc.contributor.author","Trinka, E."],["dc.contributor.author","von Oertzen, T. J."],["dc.contributor.author","Wiendl, Heinz"],["dc.contributor.author","Woermann, F."],["dc.contributor.author","Bien, Christian G."],["dc.date.accessioned","2018-11-07T09:40:31Z"],["dc.date.available","2018-11-07T09:40:31Z"],["dc.date.issued","2014"],["dc.format.extent","347"],["dc.identifier.isi","000337563600659"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33525"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","Joint Congress of European Neurology"],["dc.relation.eventlocation","Istanbul, TURKEY"],["dc.relation.issn","1468-1331"],["dc.relation.issn","1351-5101"],["dc.title","Comparative case series of GABA(B) and AMPA receptor antibodies associated with limbic encephalitis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","113"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Klinische Pädiatrie"],["dc.bibliographiccitation.lastpage","117"],["dc.bibliographiccitation.volume","228"],["dc.contributor.author","Wiese, M."],["dc.contributor.author","Schill, Fabian"],["dc.contributor.author","Sturm, Dominik"],["dc.contributor.author","Pfister, Stefan M."],["dc.contributor.author","Hulleman, Esther"],["dc.contributor.author","Johnsen, Steven A."],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2018-11-07T10:14:53Z"],["dc.date.available","2018-11-07T10:14:53Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG) belong to the most aggressive cancers in children with poor prognosis and limited therapeutic options. Therapeutic targeting of epigenetic proteins may offer new treatment options. Preclinical studies identified Enhancer of Zeste Homolog 2 (EZH2) within polycomb repressor complex 2 (PRC2) as a potential epigenetic anti-tumor target in adult GBM cells but similar inhibition studies in pediatric GBM/DIPG were still missing. Moreover, approximately 30 % of pediatric high grade gliomas (pedHGG) including GBM and DIPG harbor a lysine 27 mutation (K27M) in histone 3.3 (H3.3) which is correlated with poor outcome and was shown to influence EZH2 function. Patients, materials and methods: The present study investigated the correlation of expression of EZH2 and other PRC2 genes (EZH1, SUZ12, EED) with overall survival of pediatric GBM patients and the cytotoxic impact of EZH2 inhibition by the novel agent Tazemetostat in pediatric GBM/DIPG cells harboring either a H3.3 mutation or a H3 wildtype. Results: EZH2 gene expression does not correlate with survival of pedHGG patients, and EZH2 inhibition does not induce significant cytotoxicity in pedHGG cells independently of H3.3 mutations. Discussion and conclusion: We suggest that EZH2 inhibition might not offer an effective single agent treatment option for paedHGG patients. However, the therapeutic efficacy in combination with cytotoxic and/or other epigenetically active agents still has to be elucidated."],["dc.description.sponsorship","Menschen fur Kinder e.V."],["dc.identifier.doi","10.1055/s-0042-105292"],["dc.identifier.isi","000375862800003"],["dc.identifier.pmid","27135271"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40710"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","1439-3824"],["dc.relation.issn","0300-8630"],["dc.title","No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","171"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Neuropathologica"],["dc.bibliographiccitation.lastpage","173"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","von Bueren, André O."],["dc.contributor.author","Karremann, Michael"],["dc.contributor.author","Gielen, Gerrit H."],["dc.contributor.author","Benesch, Martin"],["dc.contributor.author","Fouladi, Maryam"],["dc.contributor.author","van Vuurden, Dannis G."],["dc.contributor.author","van Zanten, Sophie E. M. Veldhuijzen"],["dc.contributor.author","Hoffman, Lindsey M."],["dc.contributor.author","Kramm, Christof M."],["dc.date.accessioned","2020-12-10T14:10:26Z"],["dc.date.available","2020-12-10T14:10:26Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1007/s00401-018-1863-6"],["dc.identifier.eissn","1432-0533"],["dc.identifier.issn","0001-6322"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70761"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.haserratum","/handle/2/70763"],["dc.title","A suggestion to introduce the diagnosis of “diffuse midline glioma of the pons, H3 K27 wildtype (WHO grade IV)”"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]